115 related articles for article (PubMed ID: 4037733)
1. Capacity of sera from patients with primary intracranial tumors to support mitogen stimulation of blood lymphocytes. Correlation to histological tumor type.
Blomgren H; Blom U; Ullén H
Anticancer Res; 1985; 5(4):349-54. PubMed ID: 4037733
[TBL] [Abstract][Full Text] [Related]
2. Mitogen stimulation of blood lymphocytes from patients with primary intracranial tumors. Correlation to histological tumor type.
Blom U; Blomgren H; Ullén H; Collins P; Von Holst H
Anticancer Res; 1985; 5(4):343-8. PubMed ID: 4037732
[TBL] [Abstract][Full Text] [Related]
3. Microvessel density in brain tumors.
Assimakopoulou M; Sotiropoulou-Bonikou G; Maraziotis T; Papadakis N; Varakis I
Anticancer Res; 1997; 17(6D):4747-53. PubMed ID: 9494601
[TBL] [Abstract][Full Text] [Related]
4. [Immunological monitoring of brain tumors--prognosis based on T-lymphocyte subpopulations and skin testing for delayed hypersensitivity].
Yokoyama H; Nakadai M; Asou Y; Maeda T; Ogashiwa M; Takeuchi K
No To Shinkei; 1985 Feb; 37(2):193-9. PubMed ID: 3873952
[TBL] [Abstract][Full Text] [Related]
5. Absence of p53 autoantibodies in sera from glioma patients.
Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W
Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045
[TBL] [Abstract][Full Text] [Related]
6. Natural killer activity of blood lymphocytes in patients with primary intracranial tumors. Correlation to histological tumor type and anatomical site.
Ullén H; Blom U; Blomgren H
Eur J Cancer Clin Oncol; 1986 Oct; 22(10):1239-45. PubMed ID: 3816915
[TBL] [Abstract][Full Text] [Related]
7. Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors.
Elliott LH; Brooks WH; Roszman TL
J Immunol; 1984 Mar; 132(3):1208-15. PubMed ID: 6319491
[TBL] [Abstract][Full Text] [Related]
8. Immunoregulatory cell function in peripheral blood leukocytes of patients with intracranial gliomas.
Braun DP; Penn RD; Flannery AM; Harris JE
Neurosurgery; 1982 Feb; 10(2):203-9. PubMed ID: 6280097
[TBL] [Abstract][Full Text] [Related]
9. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
10. T cell adoptive immunotherapy of newly diagnosed gliomas.
Plautz GE; Miller DW; Barnett GH; Stevens GH; Maffett S; Kim J; Cohen PA; Shu S
Clin Cancer Res; 2000 Jun; 6(6):2209-18. PubMed ID: 10873070
[TBL] [Abstract][Full Text] [Related]
11. [Histological and molecular classification of gliomas].
Figarella-Branger D; Colin C; Coulibaly B; Quilichini B; Maues De Paula A; Fernandez C; Bouvier C
Rev Neurol (Paris); 2008; 164(6-7):505-15. PubMed ID: 18565348
[TBL] [Abstract][Full Text] [Related]
12. Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours.
Roszman TL; Brooks WH
Clin Exp Immunol; 1980 Feb; 39(2):395-402. PubMed ID: 6966992
[TBL] [Abstract][Full Text] [Related]
13. Blood lymphocyte subsets in patients with primary intracranial tumours. Correlation to histological tumour type and anatomical site.
Ullén H; Blom U; Blomgren H; von Holst H
Acta Neurochir (Wien); 1986; 81(3-4):100-5. PubMed ID: 3489354
[TBL] [Abstract][Full Text] [Related]
14. Neuropathology of malignant gliomas.
Bruner JM
Semin Oncol; 1994 Apr; 21(2):126-38. PubMed ID: 8153659
[TBL] [Abstract][Full Text] [Related]
15. Relation between the site of primary intracranial tumors and mitogenic responses of blood lymphocytes.
Blomgren H; Blom U; Ulén H
Cancer Immunol Immunother; 1986; 21(1):31-8. PubMed ID: 3632915
[TBL] [Abstract][Full Text] [Related]
16. Expression of vascular endothelial growth factor in tumors and plasma from dogs with primary intracranial neoplasms.
Rossmeisl JH; Duncan RB; Huckle WR; Troy GC
Am J Vet Res; 2007 Nov; 68(11):1239-45. PubMed ID: 17975980
[TBL] [Abstract][Full Text] [Related]
17. [Immunoenzyme method of determining brain-specific alpha 1-globulin in glial tumors].
Tatarinov IuS; Obukhov SK
Vopr Onkol; 1985; 31(1):76-9. PubMed ID: 2579508
[TBL] [Abstract][Full Text] [Related]
18. [Histological classification of human gliomas: state of art and controversies].
Figarella-Branger D; Bouvier C
Bull Cancer; 2005 Apr; 92(4):301-9. PubMed ID: 15888386
[TBL] [Abstract][Full Text] [Related]
19. [Immunological monitoring of brain tumors--prognosis and cellular immunity of patients with brain tumors].
Yokoyama H; Hara M; Ogashiwa M; Takeuchi K
No To Shinkei; 1983 Nov; 35(11):1103-8. PubMed ID: 6661336
[TBL] [Abstract][Full Text] [Related]
20. Cellular and humoral immunity to purified protein derivative (PPD) in PPD skin reactive and nonreactive patients with pulmonary tuberculosis: comparative analysis of antigen-specific lymphocyte proliferation and IgG antibodies.
Boras Z; Juretić A; Rudolf M; Uzarević B; Trescec A
Croat Med J; 2002 Jun; 43(3):301-5. PubMed ID: 12035136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
